Kezar Life Sciences to Present During Upcoming Virtual Investor Conferences
Kezar Life Sciences Reports Third-Quarter 2020 Financial Results and Provides Business Updates
Kezar Highlights Broad Therapeutic Potential of KZR-616 During ACR Convergence 2020
Kezar Life Sciences Announces Orphan Drug Designations for KZR-616 for the Treatment of Polymyositis and Dermatomyositis
Kezar Life Sciences to Present at Four Upcoming Virtual Medical and Scientific Conferences
